Business UpdateJul 2, 2026, 08:01 AM
OnKure to Host Virtual KOL Event on PI3Kα Inhibitors
AI Summary
OnKure Therapeutics announced it will host a virtual Key Opinion Leader (KOL) event on July 15, 2026, featuring prominent scientists Benjamin F. Cravatt, PhD, and Robert Abraham, PhD, along with company management. The event will delve into the significance of PI3Kα selectivity and OnKure's structure-based drug design approach for allosteric pan-mutant PI3Kα inhibitors. Management will also outline the strategy for its next-generation PI3Kα pan-mutant inhibitor portfolio, including OKI-345 and OKI-355, with planned IND submissions in the first half of 2027.
Key Highlights
- OnKure to host a virtual Key Opinion Leader (KOL) event on July 15, 2026, at 11:00 AM ET.
- Event will feature Benjamin F. Cravatt, PhD, and Robert Abraham, PhD, alongside company management.
- Discussion to focus on PI3Kα selectivity and structure-based drug design for inhibitors.
- Management will provide an overview of next-generation pan-mutant PI3Kα inhibitor strategy.
- Pipeline includes OKI-345 for breast cancer and OKI-355 for vascular anomalies.
- Investigational New Drug (IND) applications for OKI-345 and OKI-355 planned for H1 2027.
Price Impact
More from OKUR